| Name | Lurasidone Hydrochloride |
| Classes |
Central Nervous System Agent Psychotherapeutic Agent |
| Diseases |
Bipolar Disorder Mental Disorder Schizophrenia |
Bangla
EnglishLurasidone Hydrochloride
Lurasidone Hydrochloride belongs to a class of drugs called the atypical antipsychotics. Lurasidone is a full antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors.
Lurasidone is an atypical antipsychotic for the treatment of:
- Schizophrenia
- Depressive Episodes associated with Bipolar Disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate
Schizophrenia
- Starting dose: 40 mg per day
- Recommended Dose: 40 to 160 mg per day
Bipolar Depression
- Starting dose: 20 mg per day
- Recommended Dose: 20 to 120 mg per day
- Schizophrenia: somnolence, akathisia, extrapyramidal symptoms, and nausea
- Bipolar depression: akathisia, extrapyramidal symptoms, and somnolence
- Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack)
- Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring
- Tardive Dyskinesia: Discontinue if clinically appropriate
- Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain
- Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes.
- Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.
- Weight Gain: Gain in body weight has been observed. Monitor weight.
- Hyperprolactinemia: Prolactin elevations may occur
- Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing Lurasidone Hydrochloride if a clinically significant decline in WBC occurs in the absence of other causative factors
- Orthostatic Hypotension and Syncope: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment. In patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naïve patients, consider a lower starting dose and slower titration
Contraindication
- Contraindicated in patients hypersensitive to any component of the medication.
- Concomitant use with a strong CYP3A4 inhibitor-
- Concomitant use with a strong CYP3A4 inducer-
None known.
None known.